The global pharmaceutical packaging market is projected to grow from USD 154.78 billion in 2025 to USD 219.08 billion by 2031, with a CAGR of 5.94%. Growth is driven by increasing demand for injectable therapies, sustainable packaging solutions, and stricter regulatory traceability requirements. Key trends include the shift toward recyclable materials, adoption of prefilled syringes, and advanced barrier systems.
West Pharmaceutical Services, Inc. (WST)
Common Stock · Currency in USD · XNYS
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Company Info
SIC3841
Composite FIGIBBG000BX24N8
CIK0000105770
IPOJan 2, 1973
Sectorsurgical & medical instruments & apparatus
Highlights
Market Cap$18.37B
EPS$7.76
P/E Ratio32.80
Revenue$3.14B
Gross Profit$1.18B
Net Income$560.00M
Employees10,800
WSO72,081,610
Phone(610) 594-2900
Websitehttps://www.westpharma.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in West Pharmaceutical Services, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
West Pharmaceutical Services, Inc. (WST) has returned -7.43% so far this year and 26.81% over the past 12 months. Looking at the last ten years, WST has achieved an annualized return of 13.69%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
WST
1M3.78%
6M-6.13%
YTD-7.43%
1Y26.81%
5Y-2.99%
10Y13.69%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of West Pharmaceutical Services, Inc. (WST) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.03% | 10.15% | -0.27% | 1.39% | ||||||||
| 2025 | 3.59% | -31.76% | -3.43% | -5.90% | -0.28% | 5.24% | 9.35% | 3.21% | 6.30% | 6.76% | -0.93% | -0.12% |
| 2024 | 6.69% | -4.03% | 11.05% | -9.42% | -7.01% | -0.50% | -7.63% | 3.12% | -3.78% | 2.45% | 5.43% | 1.30% |
| 2023 | 11.45% | 18.74% | 9.85% | 5.37% | -7.48% | 14.27% | -2.95% | 10.91% | -8.58% | -14.75% | 10.18% | 0.52% |
| 2022 | -15.68% | -2.33% | 5.71% | -23.59% | -1.11% | -3.41% | 13.22% | -12.80% | -16.82% | -7.61% | 1.96% | -0.42% |
| 2021 | 5.67% | -6.64% | 0.03% | 15.69% | 5.93% | 3.19% | 14.61% | 9.53% | -5.59% | 1.15% | 2.72% | 6.04% |
| 2020 | 3.79% | -3.86% | 0.47% | 26.79% | 15.14% | 5.88% | 18.16% | 4.24% | -3.70% | -2.40% | 0.54% | 3.10% |
| 2019 | 11.90% | -3.23% | 4.86% | 11.68% | -5.64% | 9.21% | 8.94% | 5.72% | -1.85% | 0.86% | 1.49% | 2.17% |
| 2018 | 1.21% | -12.78% | 1.44% | 0.16% | 5.84% | 5.99% | 11.26% | 7.06% | 5.65% | -14.73% | 2.93% | -11.64% |
| 2017 | -0.42% | -3.03% | -2.16% | 12.92% | 5.35% | -3.00% | -6.55% | -2.53% | 10.49% | 4.89% | -1.40% | -0.91% |
| 2016 | 3.25% | 4.98% | 1.44% | 5.70% | 1.70% | -9.22% | 2.55% | 7.06% | 4.47% |
Performance Indicators
The charts below present risk-adjusted performance metrics for West Pharmaceutical Services, Inc. (WST) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of WST compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current West Pharmaceutical Services, Inc. volatility is 1.92%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 4.27B | 3.64B | 3.83B | 3.62B | 3.31B | 2.79B | 2.34B | 1.98B | 1.86B | 1.72B | 1.70B | 1.67B | 1.67B | 1.56B |
| Equity Attributable To Parent (USD) | 3.18B | 2.68B | 2.88B | 2.68B | 2.34B | 1.85B | 1.57B | 1.40B | 1.28B | 1.12B | 1.02B | 956.90M | 906.40M | 728.90M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 3.18B | 2.68B | 2.88B | 2.68B | 2.34B | 1.85B | 1.57B | 1.40B | 1.28B | 1.12B | 1.02B | 956.90M | 906.40M | 728.90M |
| Other Non-current Liabilities (USD) | 236.30M | 208.10M | 69.90M | 204.00M | 131.30M | 180.70M | - | 102.80M | 106.40M | 129.60M | 58.70M | 124.80M | 154.80M | 161.80M |
| Long-term Debt (USD) | 202.80M | 202.60M | 206.80M | 208.90M | 253.00M | 255.20M | - | 196.10M | 197.00M | 228.60M | 298.20M | 336.70M | 373.50M | 411.50M |
| Noncurrent Liabilities (USD) | 439.10M | 410.70M | 276.70M | 412.90M | 384.30M | 435.90M | 426.60M | 298.90M | 303.40M | 358.20M | 356.90M | 461.50M | 528.30M | 573.30M |
| Other Current Liabilities (USD) | 401.20M | 311.10M | 429.40M | 303.60M | 361.90M | 290.30M | 184.80M | 88.80M | 85.20M | 67.40M | 141.50M | 96.50M | 69.80M | 102.40M |
| Wages (USD) | - | - | - | - | - | - | - | 64.50M | 56.20M | 51.60M | 53.00M | 52.90M | 59.10M | 56.50M |
| Accounts Payable (USD) | 253.70M | 239.30M | 242.40M | 215.40M | 232.20M | 213.10M | 156.80M | 130.40M | 138.10M | 122.00M | 119.80M | 103.10M | 108.00M | 102.90M |
| Current Liabilities (USD) | 654.90M | 550.40M | 671.80M | 519.00M | 594.10M | 503.40M | 341.60M | 283.70M | 279.50M | 241.00M | 314.30M | 252.50M | 236.90M | 261.80M |
| Liabilities (USD) | 1.09B | 961.10M | 948.50M | 931.90M | 978.40M | 939.30M | 768.20M | 582.60M | 582.90M | 599.20M | 671.20M | 714.00M | 765.20M | 835.10M |
| Other Non-current Assets (USD) | 557.70M | 512.90M | 464.70M | 520.60M | 491.30M | 446.40M | 413.60M | 242.20M | 242.60M | 273.20M | 262.80M | 263.80M | 260.90M | 287.10M |
| Intangible Assets (USD) | 7.70M | 10.80M | 15.10M | 18.40M | 23.00M | 30.50M | 29.80M | 20.30M | 21.70M | 23.30M | 37.60M | 42.00M | 48.30M | 50.60M |
| Fixed Assets (USD) | 1.73B | 1.58B | 1.41B | 1.16B | 1.06B | 943.20M | 839.30M | 822.00M | 855.00M | 778.30M | 721.00M | 705.80M | 711.70M | 669.00M |
| Noncurrent Assets (USD) | 2.29B | 2.11B | 1.89B | 1.70B | 1.57B | 1.42B | 1.28B | 1.08B | 1.12B | 1.07B | 1.02B | 1.01B | 1.02B | 1.01B |
| Other Current Assets (USD) | 1.53B | 1.16B | 1.50B | 1.50B | 1.36B | 1.05B | 823.00M | 679.90M | 528.30M | 442.60M | 492.60M | 477.80M | 473.80M | 395.10M |
| Inventory (USD) | 443.90M | 377.00M | 434.70M | 414.80M | 378.40M | 321.30M | 235.70M | 214.50M | 215.20M | 199.30M | 181.10M | 181.50M | 176.90M | 162.20M |
| Current Assets (USD) | 1.98B | 1.54B | 1.94B | 1.92B | 1.74B | 1.37B | 1.06B | 894.40M | 743.50M | 641.90M | 673.70M | 659.30M | 650.70M | 557.30M |
| Assets (USD) | 4.27B | 3.64B | 3.83B | 3.62B | 3.31B | 2.79B | 2.34B | 1.98B | 1.86B | 1.72B | 1.70B | 1.67B | 1.67B | 1.56B |
News and Insights
Iron Mountain, US Foods, and West Pharmaceutical Services reported strong Q4 2025 earnings. Iron Mountain posted record results with 16.6% revenue growth driven by data center and digital services, projecting 10-13% revenue growth for 2026. US Foods achieved 178.8% net income growth despite softer economic conditions, while West Pharmaceutical delivered 7.5% revenue growth with strong performance in high-value product components.
Ten large-cap stocks experienced significant declines during the week of January 19-23, 2026. AeroVironment led losses with a 19.45% drop following a government stop work order. DraftKings fell 14.4% due to Massachusetts blocking sports-related contracts, while Abbott declined 12.23% after missing earnings expectations. Other major losers included AppLovin (14.68%), Shopify (13.51%), Flutter Entertainment (13.07%), and West Pharmaceutical Services (13.27%).
AbbVie announced a voluntary agreement with the Trump administration to lower drug prices for Medicaid while pledging $100 billion in U.S.-based R&D and capital investments over the next decade. In exchange, the company receives tariff exemptions and protection from future pricing mandates. AbbVie also announced a $650 million licensing deal with RemeGen for cancer drug RC148 and agreed to acquire a West Pharmaceutical Services manufacturing facility in Arizona for $175 million.
The global cell therapy packaging market is projected to grow from $404 million in 2025 to $1.22 billion by 2035, driven by personalized cell therapies and technological innovations in packaging solutions.
The global cell therapy packaging market is projected to grow from $419.57 million in 2025 to $1.27 billion by 2034, driven by increasing demand for cell and gene therapies, technological advancements, and specialized packaging solutions.
The global medical flexible packaging market is projected to grow from USD 21.48 billion in 2025 to USD 34.78 billion by 2034, with a 5.5% CAGR. Key growth drivers include rising pharmaceutical needs, sustainability focus, and increasing chronic disease prevalence.
West Pharmaceutical Services reported strong Q3 2025 earnings, beating analyst expectations with nearly 8% year-over-year sales growth and raising full-year guidance, leading to an 11% stock price increase.
West Pharmaceutical Services reported strong Q3 earnings, beating analyst estimates with $1.96 per share and raising fiscal 2025 guidance, driven by robust demand for GLP-1 product components.
Law firm investigating potential claims against West Pharmaceutical Services for allegedly misleading investors about business performance, customer demand, and product margins during February 2023-2025 period.